2-[2-(2-异丙氧基乙氧基)乙氧基]丙烷 | 81349-58-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-[2-(2-异丙氧基乙氧基)乙氧基]丙烷
• 中文别名: 2,2'-[氧代二(乙烷-2,1-二氧基)]二丙烷
• 英文名称: di-isopropyl diethylene glycol
• 英文别名: 2,2'-(Oxybis(ethane-2,1-diyloxy))bispropane；2-[2-(2-propan-2-yloxyethoxy)ethoxy]propane
• CAS: 81349-58-8
• 化学式: C₁₀H₂₂O₃
• 分子量: 190.283
• InChiKey: JHOOWURXQGAXHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二乙二醇双对甲苯磺酸酯 、 异丙醇 在 sodium 作用下， 以 四氢呋喃 为溶剂， 反应 23.0h， 以71%的产率得到2-[2-(2-异丙氧基乙氧基)乙氧基]丙烷
  参考文献：
  名称：

  Manipulating the Diastereoselectivity of Ortholithiation in Planar Chiral Ferrocenes

  摘要：

  The sense of asymmetric ortholithiation directed by a chiral oxazoline may be inverted simply by the choice of achiral ligand. Comparison of results with a number of ferrocenyl oxazoline derivatives suggests that lithiation takes place by coordination to the oxazoline nitrogen irrespective of the ligand used.

  DOI：

  10.1021/ol4013734

文献信息

• METHOD FOR PRODUCING CARBONATE COMPOUND
  申请人：Asahi Glass Company, Limited

  公开号：US20150284314A1

  公开（公告）日：2015-10-08

  The present invention relates to a production process capable of selectively producing various kinds of carbonate compounds without restraint in high yields without using toxic compounds such as phosgene and crown ethers, without producing corrosive gases such as hydrogen chloride as a by-product, and without necessity of removing the chloroform as a by-product by distillation, and to a method for producing a carbonate compound, containing reacting compound (1) with a compound having an OH group in the presence of a metal salt and 0.2 to 4.0 mol of compound (2) per mol of the metal salt to obtain a carbonate compound, in which m is an integer of 1-10, Q is an alkylene group having 1 to 4 carbon atoms, etc, and R 10 and R 11 are alkyl groups having 1 to 5 carbon atoms, etc.

  本发明涉及一种生产过程，能够在高产率下有选择地生产各种碳酸盐化合物，而不使用像光气和冠醚这样的有毒化合物，也不产生像氯化氢这样的腐蚀性气体作为副产品，也不需要通过蒸馏去除氯仿作为副产品，以及一种制备碳酸盐化合物的方法，其中包括在金属盐和化合物（1）的存在下，将化合物（1）与具有羟基的化合物反应，每摩尔金属盐添加0.2到4.0摩尔的化合物（2），以获得碳酸盐化合物，其中m是1-10的整数，Q是具有1到4个碳原子的烷基基团，R10和R11是具有1到5个碳原子的烷基基团等。
• SUPRAMETALLOGELS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20150225438A1

  公开（公告）日：2015-08-13

  The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

  该披露提供了通过过渡金属配体（例如Pd(II)-、Ni(II)-或Fe(II)-配体的A式）协调和连接自组装形成的纳米结构（例如纳米球和纳米桨轮）。该披露还提供了由二价连接剂Y连接的纳米结构的超分子复合物。提供的超分子复合物能够形成凝胶（例如水凝胶）。这些凝胶是超金属凝胶，具有出色的机械性能，不会牺牲自愈能力，并展现出高韧性和储存模量。本披露还提供了包括纳米结构或超分子复合物以及可选药剂（例如小分子）的组合物（例如凝胶），其中纳米结构和超分子复合物的纳米结构部分可以包裹并缓慢释放药剂。这些纳米结构、超分子复合物和组合物可用于将药剂输送至受体、组织或细胞，作为超吸水材料，并用于治疗疾病（例如遗传疾病、增生性疾病（例如癌症或良性肿瘤）、血液疾病、神经系统疾病、胃肠疾病（例如肝病）、脾脏疾病、呼吸系统疾病（例如肺部疾病）、疼痛症状、泌尿生殖系统疾病、肌肉骨骼状况、传染病、炎症性疾病、自身免疫疾病、精神障碍或代谢性疾病）。
• 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2113501A1

  公开（公告）日：2009-11-04

  Compounds having the formula (I): wherein the dashed line (represented by - - - - - ) represents an optional double bond; R1 is hydrogen and R2 is hydroxyethyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl ring optionally substituted with one or two hydroxy groups; R3 is hydroxy or C1-6alkoxy; n is selected from 0, 1, and 2; with the proviso that the combination where the dashed line represents a double bond, R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl ring, and n is 0, is excluded; and an N-oxide, salt, or stereoisomer thereof. Also provided are methods for the preparation of compounds of formula (I); their uses as a medicament, particularly for the treatment or prophylaxis of a sigma receptor mediated disease or condition.

  具有以下结构式（I）的化合物： 其中虚线（表示为- - - - -）代表可选的双键； R1为氢，R2为羟乙基；或者R1和R2与它们附着的氮原子一起形成一个吗啡啉环，该环可选择地被一个或两个羟基取代； R3为羟基或C1-6烷氧基； n选自0、1和2； 但是排除以下组合：虚线代表双键，R1和R2与它们附着的氮原子一起形成吗啡啉环，n为0； 以及其N-氧化物、盐或立体异构体。 此外，提供了制备结构式（I）化合物的方法；它们作为药物的用途，特别是用于治疗或预防σ受体介导的疾病或症状。
• 4,4-BIS[(ETHENYLOXY)METHYL]CYCLOHEXENE AND METHOD FOR PRODUCING SAME
  申请人：Aburai Youhei

  公开号：US20140058136A1

  公开（公告）日：2014-02-27

  A novel substance, 4,4-bis[(ethenyloxy)methyl]cyclohexene having the formula (I), which is low in odor, low in volatility, and low in skin irritability, and therefore, can be used as, for example, a starting material for inks and a starting material for electronic materials, and a method for producing the same are provided:

  提供了一种新的物质4,4-双[(乙烯氧基)甲基]环己烯，其化学式为(I)，具有低气味、低挥发性和低皮肤刺激性，因此可以用作油墨和电子材料的起始原料，同时提供了一种制备该物质的方法。
• NON-AQUEOUS PIGMENTED INKJET INKS
  申请人：Hoogmartens Ivan

  公开号：US20090270537A1

  公开（公告）日：2009-10-29

  A non-aqueous inkjet ink includes C.I. Pigment Yellow 150 and a polymeric dispersant according to Formula (I): wherein, T represents hydrogen or a polymerization terminating group; Z represents the residue of polyethyleneimine having a number-average molecular weight of at least 100; A represents an oxyalkylene carbonyl group; T-C(O)A n - represents a TPOAC-chain which is bound to Z through an amide bond; and n and m are integers wherein m is at least 2 and n is from 2 to 100; the polymeric dispersant fulfills the conditions of: W TPOAC >57 and N Amide ≧65 mol % wherein W TPOAC represents the ratio of the weight percentage of TPOAC-chains over the weight percentage of amide bonds in the polymeric dispersant; N Amide represents the mol % of amide bonds based on the total nitrogen content of the polymeric dispersant; and the values of W TPOAC and N Amide are calculated from the total nitrogen content determined by dry combustion of the polymeric dispersant and from the amine content determined through potentiometric titration in a mixture of CH 3 COOH:THF (14.5:0.5) with 0.1N aqueous perchloric acid.

  一种非水性喷墨墨水，包括C.I. Pigment Yellow 150和根据公式（I）的聚合物分散剂： 其中，T代表氢或聚合物终止基团；Z代表具有至少100的数均分子量的聚乙烯亚胺的残基；A代表氧烷基羰基基团；T-C（O）An-代表通过酰胺键与Z结合的TPOAC链；而n和m是整数，其中m至少为2，n为2至100之间； 聚合物分散剂满足以下条件： WTPOAC > 57，NAmide≧65 mol％ 其中，WTPOAC代表聚合物分散剂中TPOAC链的重量百分比与酰胺键的重量百分比之比；NAmide代表聚合物分散剂总氮含量基础上的酰胺键摩尔百分比；WTPOAC和NAmide的值是通过干燥燃烧聚合物分散剂确定的总氮含量以及在CH3COOH：THF（14.5：0.5）混合物中用0.1N的高氯酸水溶液进行电位滴定测定的胺含量计算出来的。